FDA Inspection 1182048 — BioPharma Services USA Inc.
The FDA completed an inspection of BioPharma Services USA Inc. on Oct 6, 2022 in Creve Coeur, MO. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Oct 6, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Creve Coeur, MO (United States)
Additional Details
Clinical BA/BE